Dr. Feng Li

Feng Li

Feng (Frank) Li, Ph.D., is President of Alliance Pharma; he obtained his Ph.D. degree in Bioanalytical Chemistry jointly from Concordia University and the National Institute of Scientific Research (Canadian Doping Control Center) in Montreal, Canada. Subsequently, Dr. Li did his post-doctoral fellowship at the Biomedical Mass Spectrometry Facility at the Mayo Clinic in Rochester, Minnesota. Furthermore, Dr. Li has an M.Sc. degree in Natural Product Chemistry and a B.S. in Pharmacy. He has held leadership roles in the Department of Drug Discovery Metabolism at Phoenix International Life Sciences, Inc., a major CRO at the time in Montreal, Canada, which was later acquired by MDS Pharma Services; in the Drug Analysis group in the Department of Drug Metabolism and Pharmacokinetics (DMPK) at GlaxoSmithKline; and in the Drug Metabolism group in the Department of Drug Safety and Disposition at Cephalon, Inc. Dr. Li has extensive DMPK experience in discovery and developmental phases of drug development. With more than 20 years in the pharmaceutical biotechnology, and CRO industry, he is well versed in bioanalytical techniques for both qualitative (drug metabolite identification) and quantitative (PK/TK) drug analysis and has published numerous articles in the area of drug metabolite identification and quantitation.

Dr. Michael Zhang

Dr. Michael Zhang

Michael Zhang, Ph.D., serves as Vice President of Quality at Alliance Pharma.  Prior to his current positon, Dr. Zhang was the Vice President of Operations.  Dr. Zhang has extensive experience in Analytical Chemistry, Computer Science, and Quality and Regulatory Compliance. His expertise includes development and validation of LC-MS/MS methods for analyses of biological samples and pesticide/herbicide residue samples, FDA/EPA/OECD GLP compliance, quality management systems, analytical instrumentation, software development, information technology, and computerized systems validation.  Before joining Alliance, Dr. Zhang was an Associate Director at Keystone Analytical Laboratories (a subsidiary of former PharmaNet Development Group, Inc.).  Dr. Zhang has developed numerous challenging LC-MS/MS methods for biological and agrochemical analyses, built up the IT infrastructures, and established GLP compliant laboratories and 21 CFR Part 11 compliant computerized systems at several companies.  Dr. Zhang has also worked as a software engineer at Motorola (Chicago, IL) and a Programmer Analyst at Affina (Peoria, IL).  Dr. Zhang earned his Ph.D. degree in Analytical Chemistry and M.Sc. degree in Computer Science, both from the University of Missouri-Rolla (Rolla, MO).  Dr. Zhang also holds an M.Sc. degree in Analytical Chemistry and a B.S. degree in Chemistry from the University of Science and Technology of China (Hefei, Anhui).

Dr. Zhiyang Zhao

Dr. Zhiyang Zhao

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Alliance Pharma. Dr. Zhao has over 25 years of pharmaceutical industry experience with special focus on metabolic and pharmacokinetic properties of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Alliance Pharma, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. Dr. Zhao’s extensive experience spans the entire drug discovery and development process (discovery, development, and in-/out-licensing) in oncology, metabolic, antiviral, CNS, and inflammatory diseases. Dr. Zhao’s contributions and accomplishments of integrating in vitro and in vivo ADMET (absorption, distribution, metabolism, excretion, and toxicity) information to optimize drug candidate properties are documented in over 50 peer‑reviewed scientific publications and patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology. Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and disposition. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.

Dr. Colin Barry

drcolinb.jpg

Colin Barry, Ph.D., who serves as the Sr. Director of the Bioanalysis department and the Sr. Director of Large Molecule Bioanalysis, brings more than a decade of experience in LC-MS analysis of proteins and peptides. Prior to joining Alliance, Dr. Barry led the Biologics group at SGS, a multinational CRO headquartered in Switzerland. Dr. Barry has also worked for the U.S. Food and Drug Administration (FDA) performing applied research and method development for the analysis and characterization of biopharmaceuticals. While at the FDA, Dr. Barry was awarded the Commissioner’s Special Citation for his work with the Necrotizing Enterocolitis Response Group. Dr. Barry earned his doctorate degree in Chemistry from Wake Forest University in Winston-Salem, North Carolina.  Subsequently, he did a postdoctoral fellowship at the University of Pennsylvania Perelman School of Medicine Center for Cancer Pharmacology in the laboratory of Dr. Ian Blair. Dr. Barry’s research has been published in multiple scientific journals including BloodJournal of Proteome Research, and the Journal of the American Chemical Society. In addition, he is an active member of the American Chemical Society and the American Society for Mass Spectrometry. In 2014, Dr. Barry was admitted to the U.S. Patent Bar. 

Dr. Deping Cheng

Dr. Deping Cheng

Deping Cheng, Ph.D. serves as the Director of Small Molecule Bioanalysis at Alliance Pharma. He has more than 15 years of experience in the CRO and large pharmaceutical companies collaborating on global cross-company and integrated inter-company outsourcing and collaborative global projects. He has extensive experience in working with CRO organizations in evaluating, training, mentoring, monitoring bioanalytical and pharmacological method development and data interpretation of their operations from a scientific perspective. During his 10-year tenure at Johnson & Johnson, Dr. Cheng has played a significant role in the discovery and development of 7 marketed products in several therapeutic areas, such as SGLT1/2 inhibitor drug of Canagliflozin. In addition, during his work at J&J, he has been involved in several dozen projects during the lead discovery, lead optimization, and early development stages.  Dr. Cheng earned his Ph.D., M.S., and B.S. degrees in Analytical Chemistry from Zhejiang University in China. Following the completion of his doctorate degree, Dr. Cheng completed three successive post-doctoral appointments at San Francisco State University, the University of Oklahoma, and concurrently at both The Ohio State University College of Pharmacy and The Ohio State University Comprehensive Cancer Center. During his post-doctoral work, Dr. Cheng provided bioanalysis, drug metabolism, and pharmacokinetic support for preclinical and clinical studies in the areas of oncology and HIV.